Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Enterprise software vendors are reorganizing around AI agents and unified data/context layers. Salesforce is buying Braze, ServiceNow is launching a Control Tower Alliance for agent governance, Zoom is adding a context layer, and Confluent is releasing Streamhouse. At the same time, investors such as Norwest see an opening to displace incumbent ERP and finance tools (NetSuite, Sage), while cautioning that AI should not be trusted with finance calculations. Results are uneven: Trimble gave a cautious 2027 outlook, QNX's royalty backlog passed $1.2B, and micro-cap TEN Holdings is still restructuring toward SaaS with small revenue ($640K) and one-off charges.
Late October to early November 2026 announcements show the AI era shifting from model hype to the infrastructure around it. Fortinet, Cisco and T-Mobile are focused on AI security and partner enablement. Encord and Philip Cai Zhenhui describe physical AI as bottlenecked by data and chips. Salesforce is buying Braze for AI-driven customer engagement, and Apple, NVIDIA and ASUS are pushing AI-capable hardware to market. Smaller firms such as TEN Holdings and Impinj are using cost cuts and SaaS-style models to show financial results. The set is only loosely tied to finance, with no direct trading, regulatory or fintech events beyond Intuit's AI product launches and the Salesforce deal.
The 2026 ESMO Congress drove a wave of clinical data, launches and partnerships: Incyte's PDAC collaborations with BMS and Synnovation, Summit's ivonescimab results, AstraZeneca's ZEGFROVY US launch, Astellas' CLDN18.2 real-world evidence, and Abbott's whole-genome MRD test. At the same time, capital-constrained smaller players are restructuring or leaving public markets (Spago's Nasdaq First North delisting, a SkinJect SPAC LOI, ADC Therapeutics' workforce cuts to extend runway into 2028). The result is a bifurcated sector: well-funded leaders and diagnostics/AI-enabled precision oncology are expanding, while micro-caps consolidate or exit.
A sharp Nasdaq selloff on Nov 5, 2026, which erased over $1 trillion from the Magnificent Seven and about $420 billion from Tesla and SpaceX, followed the US midterms and talk that Democrats will rein in Big Tech. Against that, Q3 results from financials (East West, TSLX, FNF, Canara HSBC Life) showed steady fee income, deposit growth and dividends, and J.P. Morgan's aerospace and defense calls show capital rotating toward selective, fundamentals-driven names. AI-finance ties are thin in these facts: Viola FinTech's 40 NYC AI portfolio companies, IEQ Capital's party for AI investors, and a European bank's use of Lenovo edge computer vision point to continued adoption despite the volatility in mega-cap tech.
Q3 2026 earnings and CEO commentary show capital concentrating in AI and defense tech: OpenAI's round closes at about $1.25T, and Shield AI raises $2.5B and buys Echodyne. Media and tech consolidation is moving ahead, with DOJ clearing Fox's purchase of Roku. Credit-market voices such as TSLX's Robert Stanley describe stable spreads, a favorable rate path and an M&A recovery expected in H1 2027 rather than by year-end. Smaller issuers (TEN Holdings, BuzzFeed, Karnalyte) are restructuring and cutting costs while building toward SaaS or development milestones, and DraftKings is spending to acquire customers in prediction markets.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedStock market today: Dow, S&P 500, Nasdaq trim losses but end sharply lower as Wall Street assesses Iran war worries
“Stock market today: Dow, S&P 500, Nasdaq trim losses but end sharply lower as Wall Street assesses Iran war worries US stocks declined but closed off session lows on Tuesday after Israel and US jets launched new strikes on Iran, as the widening conflict stoked worries about a drawn-out regional war…”
Intel will help build Elon Musk’s Terafab AI chip factory
“The Verge AI - Consumer Ai Title: Intel will help build Elon Musk’s Terafab AI chip factory Date: 2026-04-07 15:43 Source: https://www.theverge.com/transportation/907976/elon-musk-terafab-intel-ai-chip-spacex-tesla <figure> <img alt="Vector illustration of the Intel logo." src="https://platform.theverge.com/wp-content/…”
New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players
“New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players Helsinki, April 05, 2026 (GLOBE NEWSWIRE) -- As Finland’s gambling market moves toward a major regulatory shift, a new comparison platform, Suomi-kasinot.fi, has been launched to help Finnish players navigate the growing number…”
/C O R R E C T I O N - AbbVie/
“/C O R R E C T I O N - AbbVie/ In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio, issued 18-Oct-2026 by AbbVie over PR Newswire, we are advised by the company that changes have been made…”
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
“Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 1…”
Tokenization Strategic Outlook Report 2025: Emerging Interconnected Digital Ecosystems
“Tokenization Strategic Outlook Report 2025: Emerging Interconnected Digital Ecosystems Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Tokenization" report has been added to ResearchAndMarkets.com's offering…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
Robinhood's event-contract revenue rose more than sixfold to $173M in Q3, passing its crypto revenue. The CFTC is suing states over these markets, and Nasdaq plans a 23-hour day. Europe's visible stake in the dossier is MiCA, which is already forcing stablecoin changes on users.
Fintech money is moving toward AI-agent identity, payments and trading products. Our dossier is thin on EU specifics, so we say so. What it does hold is checked: Robinhood's SEC-filed results, a $35M identity round, and a Norwest investor's warning that AI should not do the maths.
Robinhood's event-contract revenue rose more than sixfold to $173M in Q3, and Nasdaq, Cboe and the CFTC are all moving toward round-the-clock trading. Europe's visible part in the dossier is MiCA's stablecoin deadline. We checked Robinhood's figures against SEC filings.
Stockholm-based BioArctic's Leqembi royalty rose about 10% in Q2 2026. Idorsia is building its deal-making team. Incyte, Vor and others report data, but the sources vary in reliability, and we flag which claims are measured and which are company statements.
Lam Research guides to an $8.6B quarter on AI chip-equipment demand, while Dow leans on cost cuts against what its CFO calls persistently high energy costs. We checked Dow's multi-year figures against SEC filings. They show why European industry is exposed to the second story, not the first.
Third-quarter calls from Lam Research, Dow and Union Pacific show a split economy. AI-driven chip demand is outrunning supply, while industrials rely on cost cuts against high energy and fuel prices. Dow's comments on European energy costs are the most direct link to European readers. Figures come from SEC-checked data and verbatim call quotes.
Dow told investors that persistently high energy costs challenge European industry economics, while Union Pacific reported fuel costs up 69%. This piece uses fidelity-checked SEC data and named, dated earnings-call quotes. It shows where the dossier is strong and where it is thin on Europe.
Dow's CFO cites $1.1B of quarterly free cash flow and no big debt maturities until 2029, while Union Pacific's fuel bill jumped 69%. Both lean on self-help and balance-sheet strength. Figures come from SEC filings and earnings-call transcripts; the transcript source is reliable only about 60% of the time.
Via News tracked a US-led fintech wave, from retail event contracts to AI-agent identity startups. Little of it is European, and the dossier names no EU regulator. We lead with Robinhood's SEC-checked figures and flag where sources diverge or are weak.
Salesforce, ServiceNow and others are rebuilding around autonomous AI agents, and governance is becoming the selling point. The dossier holds no EU-specific regulatory facts, so we say so. What it does hold is SEC-verified Salesforce financials and primary announcements.
Europe's drug regulator issued positive opinions on RASONQUE, Libtayo dosing and Trodelvy plus Keytruda this summer and autumn, just before ESMO opens in Madrid. SEC-checked figures for Summit Therapeutics show what the pipeline costs. We flag where the evidence is thin or the sources are weak.
Analysts turned more bullish on Palantir in mid-October 2026 while J.P. Morgan's lead defence analyst downgraded Leidos and warned of a weak sector. The dossier holds little European regulatory material, so we say so, and set out what was said, by whom, and how reliable the sources are.
EU regulators backed a new Libtayo dosing schedule and a Trodelvy-Keytruda combination, while US dates for Summit's ivonescimab loom. AstraZeneca's AI drug-design vision rests on forecasts, not results. Summit's checked SEC filings show the cost of a late-stage bet.
Analysts are upgrading Palantir while J.P. Morgan warns on defence stocks. The dossier holds little European-specific evidence, so we say so. We separate verified figures, analyst opinion and our own reading, and flag where the sources are weak.
EU regulators are backing newer cancer treatments, and AI is billed as the long-term engine. But the one company with checked SEC figures, Summit Therapeutics, lost $1.08 billion in FY2025 with no revenue. Several AI claims are forecasts from a source that failed our reliability check.
AI spending is spreading from chips to networking, physical-world data and customer-service software. Nvidia's audited cost of sales shows how fast. The dossier says little about EU rules, and safety scrutiny of OpenAI is rising. Verified filings are separated from company claims.
SAP, Zeta and others are launching agent platforms, while the smaller deals show money flowing to the layers that keep agents in check. Our dossier has little on EU regulation, so we say so. It does contain a clear argument that rules must be enforced by the system, and a warning not to trust AI with finance arithmetic.
A CHMP opinion for Trodelvy, a German-first Optune Pax launch and real-world German data on mogamulizumab give Europe its own oncology story in a US-heavy October. Summit's SEC-verified accounts show how costly the biggest catalyst, ivonescimab, is to reach. Some sources here fared poorly in our reliability checks.
A French networking tie-up and a Dutch equipment maker sit at the European edge of an AI-driven memory and interconnect squeeze. SEC-verified Micron filings show how fast its spending has grown. We separate the checked figures from analyst opinion and flag where the sources are weak.
Three oncology storylines are converging: new-modality drugs nearing decisions, AI-built biologics, and a care-delivery buyout. For European readers the clearest signals are an EMA committee opinion and a Swiss-based device maker's EU launch. Summit's checked SEC filings show what a late-stage bet costs. Source reliability is flagged throughout.
Verified SEC data show Micron's annual capital spending nearly doubled to $15.9bn in fiscal 2025. Meanwhile Nvidia is locking down memory supply, and France's Kalray and Bull are pursuing AI networking. Much of the supporting reporting is only partly reliable, and we show where.
The EU regulator has backed a new first-line breast cancer combination and Novocure has won a CE Mark, while US decisions on ivonescimab and a personalised mRNA vaccine arrive by 14 November. Merck's SEC-verified numbers show cash moving sharply and capex falling. Our sources vary widely in reliability, and we say where.
A European regulator backed a new first-line breast cancer combination, and a Swiss-based device maker reported record revenue while opening a German launch. Behind both sits a pipeline built on AI, mRNA and antibody-drug combinations. We separate what is verified from what is still a claim.
SEC-filed figures show Micron's capital spending almost doubled in a year and its cash pile reached $25 billion. Analysts are bullish on AI-infrastructure names but flag stretched valuations. The dossier holds little EU regulatory material, and we say so.
SEC-filed figures show Micron's capital spending nearly doubled in a year, while Europe's visible role is ASML's rally and a Kalray–Bull networking pact. Analysts' 33% to 49% upside calls come from a source whose claims held up only 22% of the time in our checks.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only about 45% of company data and only about half trust their agents. Deals from Manulife, Box and Nvidia show where the money is going. That source scores poorly on our reliability check, so we flag it.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.
